[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Submit :: Contact Us ::
:: Volume 5, Issue 1 (Spring 2015) ::
JABS 2015, 5(1): 1-13 Back to browse issues page
Metabolic Syndrome as a Risk Factor for Osteoarthritis
Alireza Askari1, Zahra Shahabfard2, Elham Ehrampoush3, Ehsan Bahramali4, Reza Homayounfar 5
1- Department of Orthopedic Surgery, Fasa University of Medical Sciences, Fasa, Iran.
2- School of Nursing, Fasa University of Medical Sciences, Fasa, Iran.
3- Department of Nutrition, Fasa University of Medical Sciences, Fasa, Iran.
4- Noncommunicable diseases research center, Fasa University of Medical Sciences, Fasa, Iran.
5- Noncommunicable diseases research center, Fasa University of Medical Sciences, Fasa, Iran. , r_homayounfar@yahoo.com
Abstract:   (9901 Views)


Metabolic syndrome refers to a set of conditions that include high blood pressure, increased insulin level in the blood, the accumulation of the excess fat around the abdomen, and increased blood lipids. In metabolic syndrome, the vast majority of these conditions are simultaneously present, and the risk of developing heart disease, stroke, and diabetes rises. Besides, osteoarthritis or degenerative joint disease is the most common joint disease in humans and is also the main cause of pain and disability in the elderly. The end result of this process is pain and reduced range of motion, and in advanced cases joint inflammation, cartilage destruction, and disability are clinical symptoms of osteoarthritis. Considering the high prevalence of these two disorders in the country and many common pathologic aspects of these two diseases such as obesity and elderly, we decided to review their relationship.


Keywords: Osteoarthritis, Metabolic syndrome, Obesity
Full-Text [PDF 392 kb]   (3404 Downloads)    
Type of Study: Review | Subject: Orthopedic
Received: 2014/09/13 | Accepted: 2015/01/10 | Published: 2015/06/16
1. 1. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis & Rheumatism. 1986;29(8):1039-49.
2. 2. Symmons D, Mathers C, Pfleger B. Global burden of osteoarthritis in the year 2000. Geneva: World Health Organization. 2003.
3. 3. Singh G, Miller JD, Lee FH, Pettitt D, Russell MW. Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination Survey. The American journal of managed care. 2002;8(15 Suppl):S383-91.
4. 4. Engström G, Gerhardsson de Verdier M, Rollof J, Nilsson P, Lohmander L. C-reactive protein, metabolic syndrome and incidence of severe hip and knee osteoarthritis. A population-based cohort study. Osteoarthritis and Cartilage. 2009;17(2):168-73.
5. 5. Puenpatom RA, Victor TW. Increased Prevalence of Metabolic Syndrome in Individuals with Osteoarthritis. Postgraduate Medicine. 2009;121(6):9-20.
6. 6. Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. The Lancet. 2011;377(9783):2115-26.
7. 7. Sowers M, Karvonen‐Gutierrez CA, Palmieri‐Smith R, Jacobson JA, Jiang Y, Ashton‐Miller JA. Knee
8. osteoarthritis in obese women with cardiometabolic
9. clustering. Arthritis Care & Research. 2009;61(10):1328- 36.
10. 8. Yoshimura N, Muraki S, Oka H, Kawaguchi H, Nakamura K, Akune T. Association of knee osteoarthritis
11. with the accumulation of metabolic risk factors such as overweight, hypertension, dyslipidemia, and impaired
12. glucose tolerance in Japanese men and women: the ROAD
13. study. The Journal of rheumatology. 2011;38(5):921-30.
14. 9. Korochina I, Bagirova G. [Metabolic syndrome and a course of osteoarthrosis].Terapevticheskii arkhiv. 2006;79(10):13-20.
15. 10. ANDERSON JJ, FELSON DT. Factors associated with osteoarthritis of the knee in the first national Health and Nutrition Examination Survey (HANES I) evidence for an association with overweight, race, and physical demands of work. American journal of epidemiology. 1988;128(1):179-89.
16. 11. Pottie P, Presle N, Terlain B, Netter P, Mainard D, Berenbaum F. Obesity and osteoarthritis: more complex than predicted! Annals of the rheumatic diseases. 2006;65(11):1403-5.
17. 12. Gabay O, Hall DJ, Berenbaum F, Henrotin Y, Sanchez
18. C. Osteoarthritis and obesity: experimental models. Joint Bone Spine. 2008;75(6):675-9.
19. 13. Chowdhury TT, Arghandawi S, Brand J, Akanji OO, Bader DL, Salter DM, et al. Dynamic compression
20. counteracts IL-1β induced inducible nitric oxide synthase
21. and cyclo-oxygenase-2 expression in chondrocyte/agarose constructs. Arthritis research & therapy. 2008;10(2):R35.
22. 14. Gosset M, Berenbaum F, Levy A, Pigenet A, Thirion S, Saffar J-L, et al. Prostaglandin E2 synthesis in cartilage explants under compression: mPGES-1 is a
23. mechanosensitive gene. Arthritis research & therapy.
24. 2006;8(4):R135.
25. 15. Fitzgerald JB, Jin M, Chai DH, Siparsky P, Fanning P, Grodzinsky AJ. Shear-and compression-induced chondrocyte transcription requires MAPK activation in cartilage explants. Journal of Biological Chemistry. 2008;283(11):6735-43.
26. 16. Gabay O, Gosset M, Levy A, Salvat C, Sanchez C, Pigenet A, et al. Stress-induced signaling pathways in hyalin chondrocytes: inhibition by Avocado–Soybean Unsaponifiables (ASU). Osteoarthritis and Cartilage. 2008;16(3):373-84.
27. 17. Shimazaki A, Wright M, Elliot K, Salter D, Millward- Sadler S. Calcium/calmodulin-dependent protein kinase II in human articular chondrocytes. Biorheology. 2006;43(3):223-33.
28. 18. Lajeunesse D. Altered subchondral osteoblast cellular metabolism in osteoarthritis: cytokines, eicosanoids, and growth factors. JOURNAL OF MUSCULOSKELETAL AND NEURONAL INTERACTIONS. 2002;2(6):504-6.
29. 19. Liu J, Liu T, Zheng Y, Zhao Z, Liu Y, Cheng H, et al. Early responses of osteoblast-like cells to different mechanical signals through various signaling pathways.
30. Biochemical and biophysical research communications.
31. 2006;348(3):1167-73.
32. 20. Sanchez C, Pesesse L, Gabay O, Delcour JP, Msika P, Baudouin C, et al. Regulation of subchondral bone osteoblast metabolism by cyclic compression. Arthritis &
33. Rheumatism. 2012;64(4):1193-203.
34. 21. Chen NX, Geist DJ, Genetos DC, Pavalko FM, Duncan RL. Fluid shear-induced NFκB translocation in osteoblasts is mediated by intracellular calcium release. Bone. 2003;33(3):399-410.
35. 22. Griffin TM, Huebner JL, Kraus VB, Guilak F. Extreme obesity due to impaired leptin signaling in mice does not cause knee osteoarthritis. Arthritis & Rheumatism. 2009;60(10):2935-44.
36. 23. Aspden RM. Obesity punches above its weight in osteoarthritis. Nature Reviews Rheumatology. 2010;7(1):65-8.
37. 24. Sowers MR, Karvonen-Gutierrez CA. The evolving
38. role of obesity in knee osteoarthritis. Current opinion in rheumatology. 2010;22(5):533.
39. 25. Gomez R, Lago F, Gomez-Reino J, Dieguez C, Gualillo O. Adipokines in the skeleton: influence on
40. cartilage function and joint degenerative diseases. Journal
41. of Molecular Endocrinology. 2009;43(1):11-8.
42. 26. Dumond H, Presle N, Terlain B, Mainard D, Loeuille D, Netter P, et al. Evidence for a key role of leptin in osteoarthritis. Arthritis & Rheumatism. 2003;48(11):3118-29.
43. 27. Faggioni R, Feingold KR, Grunfeld C. Leptin regulation of the immune response and the immunodeficiency of malnutrition. The FASEB Journal.
44. 2001;15(14):2565-71.
45. 28. Iliopoulos D, Malizos KN, Tsezou A. Epigenetic regulation of leptin affects MMP-13 expression in osteoarthritic chondrocytes: possible molecular target for osteoarthritis therapeutic intervention. Annals of the rheumatic diseases. 2007;66(12):1616-21.
46. 29. Otero M, Reino JJG, Gualillo O. Synergistic induction of nitric oxide synthase type II: In vitro effect of leptin and
47. interferon‐γ in human chondrocytes and ATDC5
48. chondrogenic cells. Arthritis & Rheumatism.
49. 2003;48(2):404-9.
50. 30. Sanna V, Di Giacomo A, La Cava A, Lechler RI, Fontana S, Zappacosta S, et al. Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses. The Journal of clinical investigation. 2003;111(2):241-50.
51. 31. Gómez R, Conde J, Scotece M, Gómez-Reino JJ, Lago F, Gualillo O. What's new in our understanding of the role of adipokines in rheumatic diseases? Nature Reviews
52. Rheumatology. 2011;7(9):528-36.
53. 32. Mutabaruka M-S, Aissa MA, Delalandre A, Lavigne M, Lajeunesse D. Research article Local leptin production in osteoarthritis subchondral osteoblasts may be responsible for their abnormal phenotypic expression. 2010.
54. 33. Motyl KJ, Rosen CJ. Understanding leptin-dependent regulation of skeletal homeostasis. Biochimie. 2012;94(10):2089-96.
55. 34. Chen T-H, Chen L, Hsieh M-S, Chang C-P, Chou D- T, Tsai S-H. Evidence for a protective role for adiponectin in osteoarthritis. Biochimica et Biophysica Acta (BBA)- Molecular Basis of Disease. 2006;1762(8):711-8.
56. 35. Laurberg TB, Frystyk J, Ellingsen T, Hansen IT, Jørgensen A, Tarp U, et al. Plasma adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid-and disease-modifying antirheumatic drug- naive compared with patients with osteoarthritis and controls. The Journal of rheumatology. 2009;36(9):1885- 91.
57. 36. Filková M, Lišková M, Hulejová H, Haluzík M, Gatterová J, Pavelková A, et al. Increased serum adiponectin levels in female patients with erosive
58. compared with non-erosive osteoarthritis. Annals of the
59. rheumatic diseases. 2009;68(2):295-6.
60. 37. Honsawek S, Chayanupatkul M. Correlation of plasma and synovial fluid adiponectin with knee osteoarthritis severity. Archives of medical research. 2010;41(8):593-8.
61. 38. Hao D, Li M, Wu Z, Duan Y, Li D, Qiu G. Synovial
62. fluid level of adiponectin correlated with levels of aggrecan degradation markers in osteoarthritis. Rheumatology international. 2011;31(11):1433-7.
63. 39. Ehling A, Schäffler A, Herfarth H, Tarner IH, Anders S, Distler O, et al. The potential of adiponectin in driving arthritis. The Journal of Immunology. 2006;176(7):4468- 78.
64. 40. Lago R, Gomez R, Otero M, Lago F, Gallego R, Dieguez C, et al. A new player in cartilage homeostasis: adiponectin induces nitric oxide synthase type II and pro- inflammatory cytokines in chondrocytes. Osteoarthritis and Cartilage. 2008;16(9):1101-9.
65. 41. Lee S, Kim J, Park M, Park Y, Lee S. Adiponectin mitigates the severity of arthritis in mice with collagen- induced arthritis. Scandinavian journal of rheumatology. 2008;37(4):260-8.
66. 42. Empana J-P. Adiponectin isoforms and cardiovascular disease: the epidemiological evidence has just begun. European heart journal. 2008.
67. 43. Frommer KW, Schäffler A, Büchler C, Steinmeyer J, Rickert M, Rehart S, et al. Adiponectin isoforms: a potential therapeutic target in rheumatoid arthritis? Annals of the rheumatic diseases. 2012.
68. 44. Nakano Y, Tajima S, Yoshimi A, Akiyama H, Tsushima M, Tanioka T, et al. A novel enzyme-linked immunosorbent assay specific for high-molecular-weight adiponectin. Journal of lipid research. 2006;47(7):1572- 82.
69. 45. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. The Journal of Immunology. 2005;174(9):5789-95.
70. 46. Šenolt L, Housa D, Vernerova Z, Jirasek T, Svobodová R, Veigl D, et al. Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Annals of the rheumatic
71. diseases. 2007;66(4):458-63.
72. 47. Gonzalez-Gay M, Garcia-Unzueta M, Gonzalez- Juanatey C, Miranda-Filloy J, Vazquez-Rodriguez T, De Matias J, et al. Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis. Clinical and experimental rheumatology. 2008;26(2):311.
73. 48. Gupta K, Shukla M, Cowland JB, Malemud CJ, Haqqi TM. Neutrophil gelatinase–associated lipocalin is expressed in osteoarthritis and forms a complex with
74. matrix metalloproteinase 9. Arthritis & Rheumatism.
75. 2007;56(10):3326-35.
76. 49. Vallon R, Freuler F, Desta-Tsedu N, Robeva A, Dawson J, Wenner P, et al. Serum amyloid A (apoSAA) expression is up-regulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases. The Journal of Immunology. 2001;166(4):2801-7.
77. 50. Bell AC, Adair LS, Popkin BM. Ethnic differences in the association between body mass index and hypertension. American Journal of Epidemiology. 2002;155(4):346-53.
78. 51. Brown CD, Higgins M, Donato KA, Rohde FC, Garrison R, Obarzanek E, et al. Body mass index and the prevalence of hypertension and dyslipidemia. Obesity
79. research. 2000;8(9):605-19.
80. 52. Conaghan PG, Vanharanta H, Dieppe PA. Is progressive osteoarthritis an atheromatous vascular disease? Annals of the rheumatic diseases. 2005;64(11):1539-41.
81. 53. Felmeden DC, Spencer CG, Belgore FM, Blann AD, Beevers DG, Lip GY. Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. American journal of hypertension. 2003;16(1):11-20.
82. 54. Karter Y, Aydın S, Curgunlu A, Uzun H, Ertürk N,
83. Vehid S, et al. Endothelium and angiogenesis in white coat
84. hypertension. Journal of human hypertension. 2004;18(11):809-14.
85. 55. Kiefer F, Neysari S, Humar R, Li W, Munk V, Battegay E. Hypertension and angiogenesis. Current pharmaceutical design. 2003;9(21):1733-44.
86. 56. Findlay DM. Vascular pathology and osteoarthritis.
87. Rheumatology. 2007;46(12):1763-8.
88. 57. Imhof H, Sulzbacher I, Grampp S, Czerny C, Youssefzadeh S, Kainberger F. Subchondral bone and cartilage disease: a rediscovered functional unit. Investigative radiology. 2000;35(10):581-8.
89. 58. Berger CE, Kröner AH, Minai-Pour MB, Ogris E, Engel A. Biochemical markers of bone metabolism in
90. bone marrow edema syndrome of the hip. Bone.
91. 2003;33(3):346-51.
92. 59. Al-Arfaj AS. Radiographic osteoarthritis and serum cholesterol. Saudi medical journal. 2003;24(7):745-7.
93. 60. Kellgren J. Osteoarthrosis in patients and populations. British medical journal. 1961;2(5243):1.
94. 61. Lippiello L, Walsh T, Fienhold M. The association of
95. lipid abnormalities with tissue pathology in human osteoarthritic articular cartilage. Metabolism. 1991;40(6):571-6.
96. 62. Stürmer T, Sun Y, Sauerland S, Zeissig I, Günther K, Puhl W, et al. Serum cholesterol and osteoarthritis. The baseline examination of the Ulm Osteoarthritis Study. The Journal of rheumatology. 1998;25(9):1827-32.
97. 63. Hart DJ, Doyle DV, Spector TD. Association between metabolic factors and knee osteoarthritis in women: the Chingford Study. The Journal of rheumatology. 1995;22(6):1118-23.
98. 64. Oliviero F, Sfriso P, Baldo G, Dayer J, Giunco S, Scanu A, et al. Apolipoprotein AI and cholesterol in
99. synovial fluid of patients with rheumatoid arthritis,
100. psoriatic arthritis and osteoarthritis. Clinical & Experimental Rheumatology. 2009;27(1):79.
101. 65. Gkretsi V, Simopoulou T, Tsezou A. Lipid metabolism and osteoarthritis: lessons from atherosclerosis. Progress in lipid research. 2011;50(2):133-40.
102. 66. Gobezie R, Kho A, Krastins B, Sarracino DA,
103. Thornhill TS, Chase M, et al. High abundance synovial fluid proteome: distinct profiles in health and osteoarthritis. Arthritis Research and Therapy. 2007;9(2):R36.
104. 67. Ruiz‐Romero C, López‐Armada MJ, Blanco FJ.
105. Proteomic characterization of human normal articular
106. chondrocytes: a novel tool for the study of osteoarthritis and other rheumatic diseases. Proteomics. 2005;5(12):3048-59.
107. 68. Wu J, Liu W, Bemis A, Wang E, Qiu Y, Morris EA, et al. Comparative proteomic characterization of articular cartilage tissue from normal donors and patients with osteoarthritis. Arthritis & Rheumatism. 2007;56(11):3675-84.
108. 69. Simopoulou T, Malizos K, Tsezou A. Lectin-like oxidized low density lipoprotein receptor 1 (LOX-1) expression in human articular chondrocytes. Clinical and experimental rheumatology. 2007;25(4):605.
109. 70. Collins-Racie L, Yang Z, Arai M, Li N, Majumdar M, Nagpal S, et al. Global analysis of nuclear receptor expression and dysregulation in human osteoarthritic articular cartilage: reduced LXR signaling contributes to catabolic metabolism typical of osteoarthritis. Osteoarthritis and Cartilage. 2009;17(7):832-42.
110. 71. Tsezou A, Iliopoulos D, Malizos KN, Simopoulou T. Impaired expression of genes regulating cholesterol efflux in human osteoarthritic chondrocytes. Journal of Orthopaedic Research. 2010;28(8):1033-9.
111. 72. Waine H, Nevinny D, Rosenthal J, Joffe I. Association of osteoarthritis and diabetes mellitus. Tufts folia medica. 1960;7:13-9.
112. 73. Cimmino M, Cutolo M. Plasma glucose concentration in symptomatic osteoarthritis: a clinical and epidemiological survey. Clinical and experimental rheumatology. 1989;8(3):251-7.
113. 74. Frey M, Barrett-Connor E, Sledge P, Schneider D, Weisman M. The effect of noninsulin dependent diabetes mellitus on the prevalence of clinical osteoarthritis. A population based study. The Journal of rheumatology. 1996;23(4):716-22.
114. 75. Schett G, Kiechl S, Bonora E, Zwerina J, Mayr A, Axmann R, et al. Vascular cell adhesion molecule 1 as a predictor of severe osteoarthritis of the hip and knee joints. Arthritis & Rheumatism. 2009;60(8):2381-9.
115. 76. Stürmer T, Brenner H, Brenner R, Günther K. Non- insulin dependent diabetes mellitus (NIDDM) and patterns of osteoarthritis: the Ulm osteoarthritis study. Scandinavian journal of rheumatology. 2001;30(3):169- 71.
116. 77. Berenbaum F. Diabetes-induced osteoarthritis: from a new paradigm to a new phenotype. Postgraduate medical journal. 2012;88(1038):240-2.
117. 78. Henrotin Y, Bruckner P, Pujol J-P. The role of reactive oxygen species in homeostasis and degradation of cartilage. Osteoarthritis and Cartilage. 2003;11(10):747- 55.
118. 79. Hiraiwa H, Sakai T, Mitsuyama H, Hamada T, Yamamoto R, Omachi T, et al. Inflammatory effect of advanced glycation end products on human meniscal cells
119. from osteoarthritic knees. Inflammation Research.
120. 2011;60(11):1039-48.
121. 80. McNulty AL, Stabler TV, Vail TP, McDaniel GE, Kraus VB. Dehydroascorbate transport in human chondrocytes is regulated by hypoxia and is a physiologically relevant source of ascorbic acid in the joint. Arthritis & Rheumatism. 2005;52(9):2676-85.
122. 81. Nah S-S, Choi I-Y, Lee C, Oh J, Kim Y, Moon H-B, et al. Effects of advanced glycation end products on theexpression of COX-2, PGE2 and NO in human osteoarthritic chondrocytes. Rheumatology. 2008;47(4):425-31.
123. 82. Nah S-S, Choi I-Y, Yoo B, Kim YG, Moon H-B, Lee C-K. Advanced glycation end products increases matrix metalloproteinase-1,-3, and-13, and TNF-α in human osteoarthritic chondrocytes. FEBS letters. 2007;581(9):1928-32.
124. 83. Rasheed Z, Akhtar N, Haqqi TM. Advanced glycation end products induce the expression of interleukin-6 and interleukin-8 by receptor for advanced glycation end
125. product-mediated activation of mitogen-activated protein
126. kinases and nuclear factor-κB in human osteoarthritis chondrocytes. Rheumatology. 2010:keq380.
127. 84. Steenvoorden M, Huizinga TW, Verzijl N, Bank RA, Ronday HK, Luning HA, et al. Activation of receptor for
128. advanced glycation end products in osteoarthritis leads to
129. increased stimulation of chondrocytes and synoviocytes. Arthritis & Rheumatism. 2006;54(1):253-63.
130. 85. Yammani RR, Carlson CS, Bresnick AR, Loeser RF. Increase in production of matrix metalloproteinase 13 by human articular chondrocytes due to stimulation with
131. S100A4: Role of the receptor for advanced glycation end
132. products. Arthritis & Rheumatism. 2006;54(9):2901-11.
133. 86. Stannus O, Jones G, Cicuttini F, Parameswaran V, Quinn S, Burgess J, et al. Circulating levels of IL-6 and TNF-α are associated with knee radiographic osteoarthritis and knee cartilage loss in older adults. Osteoarthritis and Cartilage. 2010;18(11):1441-7.
134. 87. Hurley MV. The role of muscle weakness in the pathogenesis of osteoarthritis. Rheumatic Disease Clinics of North America. 1999;25(2):283-98.
135. 88. Shakoor N, Lee KJ, Fogg LF, Block JA. Generalized vibratory deficits in osteoarthritis of the hip. Arthritis Care
136. & Research. 2008;59(9):1237-40.
137. 89. Huffman K, Kraus W. Osteoarthritis and the metabolic syndrome: more evidence that the etiology of OA is different in men and women. Osteoarthritis and cartilage/OARS, Osteoarthritis Research Society. 2012;20(7):603.
138. 90. Sridevi D, Rajeev G, Ishwarlal J. Inflammation, Oxidative Stress, and the Metabolic Syndrome. Diabetes Pathophysiology.2008(1):32-7.
139. 91. Patel SB, Reams GP, Spear RM, Freeman RH, Villarreal D. Leptin: linking obesity, the metabolic syndrome, and cardiovascular disease. Current hypertension reports. 2008;10(2):131-7.
140. 92. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arteriosclerosis, thrombosis, and vascular biology. 2004;24(5):816-23.
141. 93. Urakawa H, Katsuki A, Sumida Y, Gabazza EC, Murashima S, Morioka K, et al. Oxidative stress is
142. associated with adiposity and insulin resistance in men. The Journal of Clinical Endocrinology & Metabolism. 2003;88(10):4673-6.
143. 94. Ford ES, Mokdad AH, Giles WH, Brown DW. The metabolic syndrome and antioxidant concentrations findings from the Third National Health and Nutrition Examination Survey. Diabetes. 2003;52(9):2346-52.
144. 95. Bedard K, Krause K-H. The NOX family of ROS- generating NADPH oxidases: physiology and pathophysiology. Physiological reviews. 2007;87(1):245- 313.
145. 96. Cardona F, Tunez I, Tasset I, Montilla P, Collantes E, Tinahones F. Fat overload aggravates oxidative stress in
146. patients with the metabolic syndrome. European journal of
147. clinical investigation. 2008;38(7):510-5.
148. 97. Fortuño A, San José G, Moreno MU, Beloqui O, Díez J, Zalba G. Phagocytic NADPH oxidase overactivity underlies oxidative stress in metabolic syndrome. Diabetes. 2006;55(1):209-15.
149. 98. Gomes VA, Casella-Filho A, Chagas AC, Tanus- Santos JE. Enhanced concentrations of relevant markers of nitric oxide formation after exercise training in patients
150. with metabolic syndrome. Nitric Oxide. 2008;19(4):345-
151. 50.
152. 99. Ziskoven C, Jäger M, Zilkens C, Bloch W, Brixius K, Krauspe R. Oxidative stress in secondary osteoarthritis: from cartilage destruction to clinical presentation? Orthopedic reviews. 2010;2(2).
153. 100. Marok R, Winyard P, Coumbe A, Kus M, Gaffney K, Blades S, et al. Activation of the transcription factor
154. nuclear factor‐κB in human inflamed synovial tissue.
155. Arthritis & Rheumatism. 1996;39(4):583-91.
156. 101. Boileau C, Martel-Pelletier J, Caron J, Msika P, Guillou GB, Baudouin C, et al. Protective effects of total fraction of avocado/soybean unsaponifiables on the structural changes in experimental dog osteoarthritis: inhibition of nitric oxide synthase and matrix metalloproteinase-13. Arthritis Res Ther. 2009;11(2):R41.
157. 102. Anagnostis P, G Athyros V, Adamidou F, Florentin M, Karagiannis A. Vitamin D and cardiovascular disease: a novel agent for reducing cardiovascular risk? Current
158. vascular pharmacology. 2010;8(5):720-30.
159. 103. Kim MK, Il Kang M, Won Oh K, Kwon HS, Lee JH, Lee WC, et al. The association of serum vitamin D level with presence of metabolic syndrome and hypertension in
160. middle‐aged Korean subjects. Clinical endocrinology.
161. 2010;73(3):330-8.
162. 104. Chaganti R, Parimi N, Cawthon P, Dam T, Nevitt M,
163. Lane N. Association of 25‐hydroxyvitamin D with
164. prevalent osteoarthritis of the hip in elderly men: The
165. osteoporotic fractures in men study. Arthritis & Rheumatism. 2010;62(2):511-4.
166. 105. Bergink AP, Uitterlinden AG, Van Leeuwen JP, Buurman CJ, Hofman A, Verhaar JA, et al. Vitamin D
167. status, bone mineral density, and the development of radiographic osteoarthritis of the knee: The Rotterdam
168. Study. JCR: Journal of Clinical Rheumatology.
169. 2009;15(5):230-7.
170. 106. Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obesity reviews. 2010;11(1):11-8.
171. 107. Karvonen-Gutierrez C, Sowers M, Heeringa S. Sex dimorphism in the association of cardiometabolic characteristics and osteophytes-defined radiographic knee
172. osteoarthritis among obese and non-obese adults:
173. NHANES III. Osteoarthritis and Cartilage. 2012;20(7):614-21.
174. 108. Beattie MS, Lane NE, Hung Y-Y, Nevitt MC. Association of statin use and development and progression of hip osteoarthritis in elderly women. The Journal of
175. rheumatology. 2005;32(1):106-10.
176. 109. Clockaerts S, Van Osch G, Bastiaansen-Jenniskens YM, Verhaar J, Van Glabbeek F, Van Meurs J, et al. Statin use is associated with reduced incidence and progression of knee osteoarthritis in the Rotterdam study. Annals of the rheumatic diseases. 2012;71(5):642-7.
177. 110. Liu F-C, Huang H-S, Huang C-Y, Yang R, Chang D- M, Lai J-H, et al. A Benzamide-Linked Small Molecule HS-Cf Inhibits TNF-α-induced interferon regulatory
178. factor-1 in porcine chondrocytes: a potential disease-
179. modifying drug for osteoarthritis therapeutics. Journal of clinical immunology. 2011;31(6):1131-42.
Send email to the article author

Add your comments about this article
Your username or Email:


XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Askari A, Shahabfard Z, Ehrampoush E, Bahramali E, Homayounfar R. Metabolic Syndrome as a Risk Factor for Osteoarthritis. JABS. 2015; 5 (1) :1-13
URL: http://jabs.fums.ac.ir/article-1-643-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 5, Issue 1 (Spring 2015) Back to browse issues page
Journal of Fasa University of Medical Sciences
Persian site map - English site map - Created in 0.05 seconds with 30 queries by YEKTAWEB 4374